JP2018504911A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504911A5
JP2018504911A5 JP2017540270A JP2017540270A JP2018504911A5 JP 2018504911 A5 JP2018504911 A5 JP 2018504911A5 JP 2017540270 A JP2017540270 A JP 2017540270A JP 2017540270 A JP2017540270 A JP 2017540270A JP 2018504911 A5 JP2018504911 A5 JP 2018504911A5
Authority
JP
Japan
Prior art keywords
polypeptide
tnf
amino acid
acid sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017540270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/050052 external-priority patent/WO2016119023A1/en
Publication of JP2018504911A publication Critical patent/JP2018504911A/ja
Publication of JP2018504911A5 publication Critical patent/JP2018504911A5/ja
Pending legal-status Critical Current

Links

JP2017540270A 2015-01-29 2016-01-29 治療及び診断剤 Pending JP2018504911A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015900260 2015-01-29
AU2015900260A AU2015900260A0 (en) 2015-01-29 Therapeutic and diagnostic agents
PCT/AU2016/050052 WO2016119023A1 (en) 2015-01-29 2016-01-29 Therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
JP2018504911A JP2018504911A (ja) 2018-02-22
JP2018504911A5 true JP2018504911A5 (enExample) 2019-03-14

Family

ID=56542055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540270A Pending JP2018504911A (ja) 2015-01-29 2016-01-29 治療及び診断剤

Country Status (6)

Country Link
US (1) US20180215805A1 (enExample)
EP (1) EP3250589A4 (enExample)
JP (1) JP2018504911A (enExample)
AU (1) AU2016212707A1 (enExample)
CA (1) CA2975017A1 (enExample)
WO (1) WO2016119023A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612112B (zh) 2016-12-09 2024-03-29 阿卡斯通生物科学公司 胰岛素-fc融合物及使用方法
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
DK4186920T5 (da) 2018-06-29 2024-07-22 Akston Biosciences Corp Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
BR112022020486A2 (pt) 2020-04-10 2023-01-17 Akston Biosciences Corp Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN111696624B (zh) * 2020-06-08 2022-07-12 天津大学 基于自注意力机制的dna结合蛋白鉴定和功能注释的深度学习方法
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159916A (zh) * 2012-02-22 2014-11-19 Nvip私人有限公司 肿瘤坏死因子受体融合蛋白及其使用方法

Similar Documents

Publication Publication Date Title
JP2018504911A5 (enExample)
JP2017048194A5 (enExample)
NZ610075A (en) Cxcr2 binding polypeptides
JP2015212284A5 (enExample)
JP2016527891A5 (enExample)
JP2015525217A5 (enExample)
JP2023179457A5 (enExample)
JP2016509011A5 (enExample)
JP2018504907A5 (enExample)
SI3191511T1 (en) Improved TNF binders
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2013509879A5 (enExample)
JP2018531624A5 (enExample)
JP2012532601A5 (enExample)
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
JP2017501695A5 (enExample)
JP2012082206A5 (enExample)
JP2011155981A5 (enExample)
JP2019514367A5 (enExample)
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
HRP20200511T1 (hr) Cjepiva protiv bakterija chlamydia sp.
JP2019512693A5 (enExample)
WO2015107363A3 (en) Mycobacterial antigen composition
EA202190240A1 (ru) Варианты рекомбинантного белка
EP4269562A3 (en) Antigen binding molecules and methods of use thereof